General Information of Drug (ID: DMRWZ6T)

Drug Name
4-((1H-indol-1-yl)methyl)benzenamine Drug Info
Synonyms CHEMBL247281; 4-((1H-indol-1-yl)methyl)benzenamine; SCHEMBL14338710; BDBM50203132
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
19779451
TTD Drug ID
DMRWZ6T

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug(s) Targeting 5-HT 6 receptor (HTR6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
LU AE58054 DMWGRQD Schizophrenia 6A20 Phase 3 [2]
SB-742457 DM6L4ZT Alzheimer disease 8A20 Phase 3 [3]
AVN 211 DMVB4OS Schizophrenia 6A20 Phase 2/3 [4]
SYN120 DMDF7XB Parkinson disease 8A00.0 Phase 2 [5]
AVN 101 DMJFLBC Alzheimer disease 8A20 Phase 2 [4]
SYN-120 DMPW0UL Alzheimer disease 8A20 Phase 2 [6]
PF-05212377 DMPVQYR Alzheimer disease 8A20 Phase 2 [7]
AVN 322 DMK2LGM Cognitive impairment 6D71 Phase 2 [3]
SAM-531 DMHVJZ6 Alzheimer disease 8A20 Phase 2 [8]
SUVN-502 DMQD753 Alzheimer disease 8A20 Phase 2 [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 6 receptor (HTR6) TTJS8PY 5HT6R_HUMAN Inhibitor [1]

References

1 Further studies on the binding of N1-substituted tryptamines at h5-HT6 receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1691-4.
2 Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats. Int J Neuropsychopharmacol. 2010 Sep;13(8):1021-33.
3 5-HT6 receptors and Alzheimer's disease. Alzheimers Res Ther. 2013; 5(2): 15.
4 Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea. Curr Opin Investig Drugs. 2010 January; 11(1): 80-91.
5 Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. Nat Rev Drug Discov. 2018 Nov;17(11):804-822.
6 The Serotonin-6 Receptor as a Novel Therapeutic Target. Exp Neurobiol. 2011 December; 20(4): 159-168.
7 PF-05212377 Alzheimer's Disease (Phase 2). Pfizer.
8 Activation of 5-HT6 receptors modulates sleep-wake activity and hippocampal theta oscillation. ACS Chem Neurosci. 2013 Jan 16;4(1):191-9.
9 Novel and Potent 5-Piperazinyl Methyl-N1-aryl Sulfonyl Indole Derivatives as 5-HT6 Receptor Ligands. ACS Med Chem Lett. 2010 October 14; 1(7): 340-344.